Electronic Supplementary Material (ESI) for New Journal of Chemistry. This journal is © The Royal Society of Chemistry and the Centre National de la Recherche Scientifique 2018

Supplementary Materials

# Design and synthesis of imidazoles linearly connected to carbocyclic and heterocyclic rings via a 1,2,3-triazole linker. Reactivity of β-azolyl enamines towards heteroaromatic azides

Nikolai A. Beliaev,<sup>a</sup> Marsel Z. Shafikov,<sup>a,b</sup> Ilya V. Efimov,<sup>a</sup> Tetyana V. Beryozkina,<sup>a</sup> Gert Lubec,<sup>c</sup> Wim Dehaen,<sup>d</sup> Vasiliy A. Bakulev<sup>a\*</sup>

<sup>a</sup>Ural Federal University, 19 Mira st., Yekaterinburg 620002, Russia

v.a.bakulev@urfu.ru

<sup>b</sup>Chemistry Department, University of York, Heslington, York, YO10 5DD, UK

<sup>c</sup>Neuroproteomics, Paracelsus Medical University, 5020 Salzburg, Austria

<sup>d</sup>Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, 3001 Leuven, Belgium

# **Table of contents**

General experimental information	S2
General method for synthesis of triazoles <b>3a-f</b> and characterization data	S2
General method for synthesis of 1,2,3-triazoles 4a-j and characterization data	S4,S5
Procedure for the synthesis of compounds <b>5a</b> and <b>6a</b> (Fig. S1)	S10,S11
General method for synthesis of amidines 8a-c and characterization data	S10
References	S11
Fig. S2 Calculated geometries of triazolines 11-14 corresponding to the lowest free energy	
Conformations	S12
Fig. S3 Calculated transition state geometries corresponding to formation of triazolines 11-14 by	
1,3-dipolar cycloaddition of enamines with azides	S12
Fig. S4 Calculated transition state geometries corresponding to the degradation pathways of the	
triazolines 11-14	S13
Fig. S5 Calculated transition state geometries corresponding to the base-catalyzed transferri triazolines 11-14	ormation of S14
Table S1 Second order perturbation analysis of 13' in the NBO basis	S15
Table S2 Second order perturbation analysis of 14' in the NBO basis	S15
<sup>1</sup> H and <sup>13</sup> C spectra of all compounds	S16

#### **General experimental information**

All melting points were determined with a Stuart SMP3 apparatus and are uncorrected. IR spectra were obtained with Bruker Alpha (NPVO, ZnSe) IR-Fur spectrometer. <sup>1</sup>H NMR and <sup>13</sup>C NMR spectra were recorded on a Bruker Avance II spectrometer with DMSO-d<sub>6</sub> or CDCl<sub>3</sub> as the solvent (400 and 100 MHz, respectively) using Me<sub>4</sub>Si as an internal standard. <sup>1</sup>H NMR data are reported as the chemical shift in parts per million, multiplicity (s, singlet; d, doublet; t, triplet; m, multiplet), coupling constant in hertz, and number of protons. High-resolution mass spectra (HRMS) were obtained on Bruker impact HD Q-TOF analyser in the ESI mode. Mass spectra were recorded with Shimadzu GCMS-QP2010 Ultra instrument in electron ionization (EI) mode. Electron energy - 70eV. The reactions were monitored by analytical TLC on aluminium foil plates with 0.2 mm silica gel with a fluorescent indicator visualed under UV light. The column chromatography was performed with 60–120 mesh silica gel.

The calculations were conducted utilizing Gaussian 09 D.01<sup>1</sup> code with DFT approach using mPW1K density functional,<sup>2,3</sup> specially designed for kinetics by Truhlar group, with 6-311+++(d,p) basis set on all atoms and superfine density grid. Conductor-like polarizable continuum solvation model C-PCM<sup>4,5</sup> was applied to simulate the solvation effect of N,N-dimethyformamide (DMF) – the solvent used in the experimental work. The geometry optimization procedures were performed with "tight" optimization criteria. Vibrational analysis proved that each of the obtained relaxed geometry represents a minimum and each transition state geometry represents a first-order saddle point on the potential energy surface. Calculation of internal reaction coordinates (IRC) with the transition state geometries proved them connecting respective starting materials with products as reported. NBO analyses of the calculated structures was carried out with NBO 6.0 software.<sup>6</sup>

#### General method for synthesis of triazoles 3a-f.

A mixture of enamine 1 (1 mmol), appropriate azide 2 (1 mmol) and DMF (0.6 mL) was stirred for 1-2 h at 100 °C (for compounds 3e and 3f – 3 hours at 130–140 °C). After cooling ethanol (5 mL) was added to the reaction mixture and after 10 min of stirring the precipitate was filtered off, washed with ethanol and dried.



**1-(4-Chlorophenyl)-4-(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazole** (3a). Synthesized from enamine **1c** and azide **2a**. Reaction's time is 1.5 h Yellowish powder; yield 0.176 g (58%); m. p. 236–237 °C;

IR (v/cm<sup>-1</sup>) 1500; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  3.85–3.99 (s, 3H, NCH<sub>3</sub>), 7.60–7.71 (m, 2H, *J* 9.0 Hz, HAr), 7.98 (s, 1H, CH), 8.02–8.11 (m, 2H, *J* 9.0, HAr), 9.35 (s, 1H, CH); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  34.3 (NCH<sub>3</sub>), 122.1 (2C<sup>Ar</sup>), 122.2 (C-5<sup>imidaz</sup>), 125.9 (C-5<sup>triaz</sup>), 130.0 (2C<sup>Ar</sup>), 133.56 (C<sup>Ar</sup>), 134.8 (C-4<sup>triaz</sup>), 134.9 (C<sup>Ar</sup>), 138.5 (C-2<sup>imidaz</sup>), 144.1 (C-4<sup>imidaz</sup>); MS-EI (*m*/*z*) 304 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>12</sub>H<sub>9</sub>ClN<sub>6</sub>O<sub>2</sub>: C, 47.30; H, 2.98; N, 27.58. Found: C, 47.19; H, 3.37; N, 27.96. Supplementary crystallographic data for the compound **3a** (CCDC 1580078) can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data request/cif.



1-(4-Chlorophenyl)-4-(1-methyl-5-nitro-1H-imidazol-4-yl)-1H-1,2,3-triazole (3b). Synthesized from enamine 1d and azide 2a. Reaction's time is 1.5 h Pink powder; yield 0.267 g (88%); m. p. 249–250°C; IR (v/cm<sup>-1</sup>) 3181, 3094, 3042, 3013, 1587, 1494; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ ) δ 4.01 (s, 3H, NCH<sub>3</sub>), 7.57–7.68 (m, 2H, *J* 9.0 Hz, HAr), 7.98–8.07 (m, 2H, *J* 9.0 Hz, HAr), 8.12 (s, 1H, CH), 9.14 (s, 1 H, CH); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ ) δ 35.6 (NCH<sub>3</sub>), 122.7 (2C<sup>Ar</sup>), 124.1 (C-5<sup>triaz</sup>), 130.3 (2C<sup>Ar</sup>), 133.9 (C<sup>Ar</sup>), 134.0 (C<sup>Ar</sup>), 135.6 (C-4<sup>triaz</sup>), 135.8 (C-4<sup>triaz</sup>), 140.7 (C-2<sup>imidaz</sup>), 142.3 (C-5<sup>imidaz</sup>); MS-EI (*m/z*) 304 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>12</sub>H<sub>9</sub>ClN<sub>6</sub>O<sub>2</sub>: C, 47.30; H, 2.98; N, 27.58. Found: C, 47.24; H, 2.73; N, 27.73.



**4-(1-Methyl-4-nitro-1H-imidazol-5-yl)-1-(4-nitrophenyl)-1H-1,2,3-triazole (3c).** Synthesized from enamine **1c** and azide **2b**. Reaction's time is 1.2 h . Yellowish powder; yield 0.277 g (88%); m. p. Calcd (%) for  $C_{12}H_9N_7O_4$ : C, 45.72; H, 2.88; N, 31.10. Found: C, 46.08; H, 3.15; N, 30.95.



**4-(1-Methyl-5-nitro-1H-imidazol-4-yl)-1-(4-nitrophenyl)-1H-1,2,3-triazole** (3d). Synthesized from enamine 1d and azide 2b. Reaction's time is 1.0 h. Pink powder; yield 0.214 (68%); m. p. > 300 °C; IR (v/cm<sup>-1</sup>) 1497, 1335; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  4.02 (s, 3H, CH<sub>3</sub>), 8.13 (s, 1H, CH), 8.31–8.41 (m,

2H, *J* 9.3 Hz, HAr), 8.41–8.51 (m, 2H, *J* 9.3 Hz, HAr), 9.36 (s, 1H, H-5); <sup>13</sup>C NMR (101 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  35.3 (NCH<sub>3</sub>), 121.1 (2C<sup>Ar</sup>), 123.9 (C-5<sup>triaz</sup>), 125.4 (2C<sup>Ar</sup>), 133.1 (C-4<sup>imidaz</sup>), 135.2 (C-5<sup>imidaz</sup>), 140.6 (C-4<sup>triaz</sup>), 140.7 (C<sup>Ar</sup>), 141.9 (C-2<sup>imidaz</sup>), 147.06 (C<sup>Ar</sup>); MS-EI (*m*/*z*) 315 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>12</sub>H<sub>9</sub>N<sub>7</sub>O<sub>4</sub>: C, 45.72; H, 2.88; N, 31.10. Found: C, 45.42; H, 3.08; N, 30.83.



Ethyl 2-(4-(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazol-1-yl)acetate (3e). Synthesized from enamine 1c and azide 2c. Reaction's time is 3h. Pink powder; yield 0.126 g (45%); m. p. 133–135 °C; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  1.30 (t, 3H, *J* 7.1 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.92 (s, 3H, NCH<sub>3</sub>), 4.24 (q, 2H, *J* 7.1 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 5.47 (s, 2H, CH<sub>2</sub>), 7.91 (s, 1H, CH), 8.75 (s, 1H, CH); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  13.9 (CH<sub>3</sub>), 34.6 (NCH<sub>3</sub>), 50.6 (NCH<sub>2</sub>), 61.6 (OCH<sub>2</sub>), 122.8 (C-5<sup>imidaz</sup>), 129.4 (C-5<sup>triaz</sup>), 133.7 (C-4<sup>triaz</sup>), 138.3 (C-4<sup>imidaz</sup>), 138.3 (C-2<sup>imidaz</sup>), 166.9 (C=O); MS-EI (*m*/*z*) 280 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>10</sub>H<sub>12</sub>N<sub>6</sub>O<sub>4</sub>: C, 42.86; H, 4.32; N, 29.99. Found: C, 43.05; H, 4.47; N, 30.18.



Ethyl 2-(4-(1-methyl-5-nitro-1H-imidazol-4-yl)-1H-1,2,3-triazol-1-yl)acetate (3f). Synthesized from enamine 1d and azide 2c. Reaction's time is 3h. Pink powder; yield 0.148 g (53%); m. p. 185–186 °C; IR ( $\nu$ /cm<sup>-1</sup>) 1736, 1503, 1356, 1268; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  1.27 (t, 3H, *J* 7.1 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 3.98 (s, 3H, NCH<sub>3</sub>), 4.22 (q, 2H, *J* 7.1 Hz, OCH<sub>2</sub>CH<sub>3</sub>), 5.44 (s, 2H, CH<sub>2</sub>), 8.09 (s, 1H, CH), 8.64 (s, 1H, CH); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  13.9 (CH<sub>3</sub>), 35.4 (NCH<sub>3</sub>), 50.4 (NCH<sub>2</sub>), 61.5 (OCH<sub>2</sub>), 127.4 (C-4<sup>triaz</sup>), 134.2 (C-5<sup>triaz</sup>), 134.6 (C-4<sup>imidaz</sup>), 138.8 (C-5<sup>imidaz</sup>), 142.0 (C-2<sup>imidaz</sup>), 167.1 (C=O); MS-EI (*m/z*) 280 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>10</sub>H<sub>12</sub>N<sub>6</sub>O<sub>4</sub>: C, 42.86; H, 4.32; N, 29.99. Found: C, 43.12; H, 4.01; N, 30.34.

### General method for synthesis of 1,2,3-triazoles 4a, d, g, i.

A mixture of enamine 1 (1 mmol), appropriate azide 2 (1 mmol) and DMF (0.4 mL) was stirred for 12-16 h at room temperature. Ethanol (5 mL) was added to the reaction mixture and after 10 min of stirring the formed precipitate of dimethylammonium salt of compound 4 was filtered off, washed with ethanol and dried. This salt was suspended in 1% nitric acid solution in water (10 mL) and stirred for 10 min. The solids were filtered off and washed with water. Crude products were crystallized from ethanol (4a, d) or refluxed in ethanol (10 mL) for 10 min and filtered off (4g, i).

## General method for synthesis of 1,2,3-triazoles 4b, c, f.

A mixture of enamine 1 (1 mmol), appropriate azide 2 (1 mmol) and DMF (0.4 mL) was stirred for 13-16 h at room temperature. Ethanol (5 mL) was added to the reaction mixture and after 10 min of stirring the formed precipitate was filtered off, washed with ethanol and dried.



Methyl 5-[1-(4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazol-4-yl]-1,2,3-thiadiazole-4-carboxylate (4a). Synthesized from enamine 1a and azide 2e; reaction's time is 14 h. Yellowish powder. Yield 0.171 g (53%); m.p. 241–242 °C; IR (v/cm<sup>-1</sup>) 3155, 2952, 2552, 1741, 1499, 1358; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  4.03 (s, 3H, OCH<sub>3</sub>), 7.08 (s, 1H, CH<sup>imidaz</sup>), 9.04 (s, 1H, H-5); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  53.0 (OCH<sub>3</sub>), 127.3 (C-5<sup>triaz</sup>), 128.6 (C-5<sup>triaz</sup>), 133.7 (C-4<sup>imidaz</sup>), 134.9 (C-4<sup>triaz</sup>), 135.3 (C-2<sup>imidaz</sup>), 146.6 (C-5<sup>thiadiaz</sup>), 151.1 (C-4<sup>thiadiaz</sup>), 160.7 (C=O). HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 323.0308, calcd for C<sub>9</sub>H<sub>6</sub>N<sub>8</sub>O<sub>4</sub>S 323.0305; Anal. Calcd (%): C, 33.54; H, 1.88; N, 34.77. Found: C, 33.39; H, 1.50; N, 34.66.



Methyl 5-[1-(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazol-4-yl]-1,2,3-thiadiazole-4carboxylate (4b). Synthesized from enamine 1a and azide 2d; reaction's time is 14 h. Yellowish powder. Yield 0.275 g (82%), m. p. 230 °C (decomp.); IR (v/cm<sup>-1</sup>) 1727, 1608, 1525, 1514, 1338; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.64 (s, 1H, NCH<sub>3</sub>), 4.04 (s, 3H, OCH<sub>3</sub>), 8.14 (s, 1H, CH<sup>imid</sup>), 9.49 (s, 1H, H-5); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  32.4 (NCH<sub>3</sub>), 53.0 (OCH<sub>3</sub>), 122.4 (C-5<sup>imidaz</sup>), 130.1 (C-5<sup>triaz</sup>), 135.3 (C-4<sup>triaz</sup>), 136.3 (C-2<sup>imidaz</sup>), 139.5 (C-4<sup>imidaz</sup>), 146.7 (C-5<sup>thiadiaz</sup>), 150.8 (C-4<sup>thiadiz</sup>), 160.6 (C=O). HRMS (ESI) [M+H<sup>+</sup>] found *m/z* 337.0460, calcd for C<sub>10</sub>H<sub>8</sub>N<sub>8</sub>O<sub>4</sub>S 337.0462; Anal. Calcd (%): C, 35.72; H, 2.40; N, 33.32. Found: C, 35.89; H, 2.58; N, 33.02.



Methyl 5-(1-(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazol-4-yl)-3-phenylisoxazole-4carboxylate (4c). Synthesized from enamine 1b and azide 2d; reaction's time is 16 h. Yellow powder. Yield 0.182 g (46%); m. p. 187–188 °C; IR (v/cm<sup>-1</sup>) 1718, 1609, 1511, 1337; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$ 3.66 (s, 3H, NCH<sub>3</sub>), 3.77 (s, 3H, OCH<sub>3</sub>), 7.45–7.59 (m, 3H, HAr), 7.66 (m, 2H, HAr), 8.14 (s, 1H, CH<sup>imidaz</sup>), 9.46 (s, 1H, H-5); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  32.5 (NCH<sub>3</sub>), 52.3 (OCH<sub>3</sub>), 108.5 (C-4<sup>izoxaz</sup>), 122.5 (C-5<sup>imidaz</sup>), 127.4 (C<sup>Ph</sup>), 128.3 (2C<sup>Ph</sup>), 129.0 (2C<sup>Ph</sup>), 130.2 (C<sup>Ph</sup>), 131.5 (C-5<sup>triaz</sup>), 134.6 (C-4<sup>triaz</sup>), 136.3 (C-2<sup>imidaz</sup>), 139.4 (C-4<sup>imidaz</sup>), 161.0 (C=O), 162.4 (C-3<sup>izoxaz</sup>), 163.1 (C-5<sup>izoxaz</sup>). HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 396.1053, calcd for C<sub>17</sub>H<sub>13</sub>N<sub>7</sub>O<sub>5</sub> 396.1051; Anal. Calcd (%): C, 51.65; H, 3.31; N, 24.80. Found: C, 51.31; H, 2.97; N, 24.86.



Methyl 5-(1-(4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazol-4-yl)-3-phenylisoxazole-4-carboxylate (4d). Synthesized from enamine 1b and azide 2e; reaction's time is 16 h. White powder. Yield 0.198 g (52%), m. p. 219 °C (decomp.); IR (v/cm<sup>-1</sup>) 1736, 1613, 1524, 1361; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.78 (s, 3H, OCH<sub>3</sub>), 7.43–7.59 (m, 3H, HAr), 7.60–7.71 (m, 2H, HAr), 7.96 (s, 1H, CH<sup>imid</sup>), 9.40 (s, 1H, H-5); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  52.2 (OCH<sub>3</sub>), 108.3 (C-4<sup>isoxaz</sup>), 127.3 (C-5<sup>isoxaz</sup>), 127.4 (C-5<sup>imidaz</sup>), 128.3 (2C<sup>Ph</sup>), 129.0 (2C<sup>Ph</sup>), 129.9 (C-5<sup>triaz</sup>), 130.2 (C<sup>Ph</sup>), 134.0 (C-4<sup>imidaz</sup>), 134.2 (C-4<sup>triaz</sup>), 135.6 (C-2<sup>imidaz</sup>), 161.1 (C=O), 162.4 (C<sup>Ph</sup>), 163.4 (C-3<sup>isoxaz</sup>). HRMS (ESI) [M+H]<sup>+</sup> found *m*/*z* 382.0896, calcd for C<sub>16</sub>H<sub>11</sub>N<sub>7</sub>O<sub>5</sub> 382.0894; Anal. Calcd (%): C, 50.40; H, 2.91; N, 25.71. Found: C, 50.54; H, 2.65; N, 25.54.



Ethyl 1-methyl-5-[4-(1-methyl-4-nitro-1*H*-imidazol-5-yl)-1*H*-1,2,3-triazol-1-yl]-1*H*-imidazole-4carboxylate (4e). A mixture of azide 2f (1 mmol), enamine 1c (1 mmol) and DMF (0.4 mL) was stirred at 100°C for 12 h. Ethanol (5 ml) was added to the cooled reaction mixture and the formed precipitate was filtered off, washed with ethanol and dried. Pink powder. Yield 0.087 g (25%), m. p. 230–232 °C; IR (v/cm<sup>-1</sup>) 3108, 1703, 1511, 1330; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  1.01 (t, *J* 7.0 Hz, 3H, CH<sub>3</sub>), 3.85 (s, 3H, CH<sub>3</sub>), 3.97, (s, 3H, CH<sub>3</sub>), 4.13 (q, *J* 7.0 Hz, 2H, OCH<sub>2</sub>) 8.06 (s, 1H, CH<sup>imid</sup>), 8.15 (s, 1H, CH<sup>imid</sup>), 9.02 (s, 1H, CH<sup>iriaz</sup>); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>)  $\delta$  13.5 (CH<sub>3</sub>), 34.3 (NCH<sub>3</sub>), 34.9 (NCH<sub>3</sub>), 60.7 (OCH<sub>2</sub>), 116.4 (C-5<sup>imidaz</sup>), 122.4 (C-5<sup>imidaz</sup>), 130.0 (C-5<sup>triaz</sup>), 133.1 (C-4<sup>triaz</sup>), 138.4 (C-4<sup>imidaz</sup>), 138.5 (C-2<sup>imidaz</sup>), 140.6 (C-2<sup>imidaz</sup>), 144.0 (C-4<sup>imidaz</sup>), 158.0 (C=O). HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 347.1212, calcd for C<sub>13</sub>H<sub>14</sub>N<sub>8</sub>O<sub>4</sub> 347.1211.



**1,4-Bis(1-methyl-4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazole (4f).** Synthesized from enamine **1c** and azide **2d**; reaction's time is 13 h. Orange powder. Yield 0.198 g (62%); m. p. 207 °C (decopm. with explosion); IR (v/cm<sup>-1</sup>) 1608, 1516, 1326; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.65 (s, 3H, NCH<sub>3</sub>), 3.96 (s, 3H, NCH<sub>3</sub>), 7.99 (s, 1H, CH<sup>imid</sup>), 8.11 (s, 1H, CH<sup>imid</sup>), 9.26 (s, 1H, CH<sup>triaz</sup>); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  32.4 (NCH<sub>3</sub>), 34.5 (NCH<sub>3</sub>), 121.7 (C-5<sup>imidaz</sup>), 122.7 (C-5<sup>imidaz</sup>), 131.7 (C-5<sup>triaz</sup>), 134.1 (C-4<sup>triaz</sup>), 136.3 (C-2<sup>imidaz</sup>), 138.7 (C-2<sup>imidaz</sup>), 139.3 (C-4<sup>imidaz</sup>), 144.3 (C-4<sup>imidaz</sup>). HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 320.0851, calcd for C<sub>10</sub>H<sub>9</sub>N<sub>9</sub>O<sub>4</sub> 320.0850; Anal. Calcd (%): C, 37.62; H, 2.84; N, 39.49. Found: C, 37.82; H, 3.10; N, 39.44.



**4-(1-Methyl-4-nitro-1H-imidazol-5-yl)-1-(4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazole** (4g). Synthesized from enamine **1c** and azide **2e**; reaction's time is 12 h. White powder. Yield 0.156 g (51%), m. p. 217 °C (decopm. with explosion); IR (v/cm<sup>-1</sup>) 1587, 1524, 1360; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.94 (s, 3H, NCH<sub>3</sub>), 7.97 (s, 1H, CH<sup>imid</sup>), 8.01 (s, 1H, CH<sup>imid</sup>), 9.18 (s, 1H, CH<sup>triaz</sup>); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  34.4 (NCH<sub>3</sub>), 121.8 (C-5<sup>imidaz</sup>), 127.0 (C-5<sup>imidaz</sup>), 130.3 (C-5<sup>triaz</sup>), 133.4 (C-4<sup>imidaz</sup>), 133.7 (C-4<sup>triaz</sup>), 135.2 (C-2<sup>imidaz</sup>), 138.6 (C-2<sup>imidaz</sup>), 144.2 (C-4<sup>imidaz</sup>). HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 306.0696, calcd for C<sub>9</sub>H<sub>7</sub>N<sub>9</sub>O<sub>4</sub> 306.0694; Anal. Calcd (%): C, 35.42; H, 2.31; N, 41.30. Found: C, 35.06; H, 2.44; N, 41.42.



Methyl5-(1-(4-(ethoxycarbonyl)-1-methyl-1H-imidazol-5-yl)-1H-1,2,3-triazol-4-yl)-3-phenylisoxazole-4-carboxylate (4h). A mixture of enamine 2f (1 mmol), enamine 1b (1 mmol) and DMF(0.4 mL) was stirred at 100°C for 12 h. After cooling, the reaction mixture was separated by columnchromatography (silica gel, ethyl acetate). The fraction containing substance with  $R_f$  0.36 was collected.Yellowish powder; yield 0.173 g (41%); m. p.145–148 °C; IR (v/cm<sup>-1</sup>) 3119, 1720, 1446, 1226, 1131; <sup>1</sup>HNMR (400 MHz, DMSO- $d_6$ )  $\delta$  1.06 (t, J 7.0 Hz, 3H, CH<sub>3</sub>), 3.74 (s, 3H, CH<sub>3</sub>), 3.98 (s, 3H, CH<sub>3</sub>), 4.14 (q, J 7.0Hz, 2H, OCH<sub>2</sub>), 7.40–7.60 (m, 3H, HPh), 7.60–7.75 (m, 2H, HPh), 8.11 (s, 1H, CH<sup>imid</sup>), 9.16 (s, 1H, CH<sup>iriaz</sup>);<sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  13.4 (CH<sub>3</sub>), 34.9 (NCH<sub>3</sub>), 52.2 (OCH<sub>3</sub>), 60.8 (OCH<sub>2</sub>), 107.9 (C-4<sup>isoxaz</sup>),116.4 (C-5<sup>imidaz</sup>), 127.5 (CPh), 128.4 (CPh), 128.9 (CPh), 129.6 (C-5<sup>triaz</sup>), 130.2 (CPh), 133.7 (C-4<sup>triaz</sup>), 138.3 (C-5<sup>imidaz</sup>), 140.6 (C-2<sup>imidaz</sup>), 158.0 (C=O<sup>imidaz</sup>), 161.3 (C=O<sup>isoxaz</sup>), 162.2 (C-3<sup>isoxaz</sup>), 163.8 (C-5<sup>isoxaz</sup>). MS-EI (m/z)422 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>20</sub>H<sub>18</sub>N<sub>6</sub>O<sub>5</sub>: C, 56.87; H, 4.30; N, 19.90. Found: C, 59.94; H, 4.26; N, 19.89.



4-(1-Methyl-5-nitro-1H-imidazol-4-yl)-1-(4-nitro-1H-imidazol-5-yl)-1H-1,2,3-triazole (4i). Synthesized from enamine 1d and azide 2e; reaction's time is 12 h. White powder. Yield 0.201 g (66%); 290 °C (decopm. with explosion); IR ( $\nu$ /cm<sup>-1</sup>) 1533, 1523, 1371, 1356; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 4.02 (s, 3H, NCH<sub>3</sub>), 7.99 (s, 1H, CH), 8.13 (s, 1H, CH), 9.09 (s, 1H), 14.88 (NH); <sup>13</sup>C NMR (100 MHz, DMSO-*d*<sub>6</sub>) δ 35.7 (NCH<sub>3</sub>), 127.3 (C-5<sup>imidaz</sup>), 128.4 (C-5<sup>triaz</sup>), 133.6 (C-4<sup>triaz</sup>), 134.8 (C-4<sup>imidaz</sup>), 135.1 (C-5<sup>imidaz</sup>), 135.7 (C- 2<sup>imidaz</sup>), 139.5 (C-4<sup>imidaz</sup>), 142.4 (C-2<sup>imidaz</sup>); HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 306.0696, calcd for C<sub>9</sub>H<sub>7</sub>N<sub>9</sub>O<sub>4</sub> 306.0694; Anal. Calcd (%): C, 35.42; H, 2.31; N, 41.30. Found: C, 35.42; H, 2.31; N, 41.30.



Methyl 1-(1-methyl-4-nitro-1H-imidazol-5-yl)-3'-phenyl-1H,3'H-[4,4'-bi(1,2,3-triazole)]-5'carboxylate (4j) and N,N-dimethyl-N'-(1-methyl-4-nitro-1H-imidazol-5-yl)formimidamide (5a). A mixture of 5-azido-1-methyl-4-nitro-1*H*-imidazole (2d) (1 mmol), methyl 5-[(*E*)-2-(dimethylamino)ethenyl]-1-phenyl-1*H*-1,2,3-triazole-4-carboxylate (1e) (1 mmol) and DMF (0.2 mL) was stirred for 16 h at room temperature. The reaction mixture was diluted with water (5 mL), the precipitate was filtered off, washed with water, dried and purified by column chromatography (EtOAc/EtOH 9:1). Two compounds (4j (major,  $R_f$ 0.41) and 5a (minor,  $R_f$  0.27)) were separated.

**4j**: white powder; yield 0.130 g (33%); m.p.187–189 °C; IR (v/cm<sup>-1</sup>): 3153, 3111, 2918, 1736, 1513, 1204; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.57 (s, 3H, NCH<sub>3</sub>), 3.88 (s, 3H, OCH<sub>3</sub>), 7.44–7.58 (m, 5H, HPh), 8.08 (s, 1H, CH<sup>inid</sup>), 9.12 (s, 1H, CH<sup>triaz</sup>); <sup>13</sup>C NMR (100 MHz, DMSO)  $\delta$  32.3, 39.5, 52.1, 122.6, 125.6, 129.4, 130.2, 130.8, 131.9, 132.8, 135.7, 136.3, 137.2, 139.3, 160.5; HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 396.1162, calcd for C<sub>16</sub>H<sub>13</sub>N<sub>9</sub>O<sub>4</sub> 396.1163; Anal. Calcd (%): C, 48.61; H, 3.31; N, 31.89. Found: C, 48.39; H, 3.42; N, 31.73.

5a: yellow crystals; yield 0.020 g (10%), m. p.142–144 °C. Spectral data of compound 5a see below.



**N,N-Dimethyl-N'-(1-methyl-4-nitro-1H-imidazol-5-yl)formimidamide (5a).** A mixture of 5-azido-1-methyl-4-nitro-1*H*-imidazole (**2d**) (1 mmol), (*E*)-*N*,*N*-dimethyl-2-(1-methyl-5-nitro-1*H*-imidazol-4yl)ethenamine **1d** (1 mmol) and DMF (0.4 mL) was stirred for 48 h at room temperature. The reaction mixture was diluted with ethanol (10 mL) and insoluble part was filtered off, washed with ethanol and dried to give compound **6** as a mixture with 20–30% of unknown impurities. The filtrate was evaporated in vacuum to dryness and the residue was separated by column chromatography (silica gel, EtOAc–ethanol 9:1). Fractions with  $R_f 0.27$  were collected and the solvent was evaporated in vacuum to dryness to give amidine **5a**.

**5a**: Yield 0.110 g (56%). Yellow crystals; m. p.142–144 °C; IR (v/cm<sup>-1</sup>): 3105, 2916, 2808, 1631, 1523; <sup>1</sup>H NMR (400 MHz, DMSO- $d_6$ )  $\delta$  3.04 (s, 3H, NCH<sub>3</sub>), 3.11 (s, 3H, NCH<sub>3</sub>), 3.39 (s, 3H, NCH<sub>3</sub>), 7.46 (s, 1H, CH<sup>imid</sup>), 8.33 (s, 1H, CH=); <sup>13</sup>C NMR (100 MHz, DMSO- $d_6$ )  $\delta$  30.6 (N(CH<sub>3</sub>)<sub>2</sub>), 34.2 (N(CH<sub>3</sub>)<sub>2</sub>), 40.6 (NCH<sub>3</sub>), 132.9 (C-2<sup>imidaz</sup>), 133.4 (C-5<sup>imidaz</sup>), 144.6 (C-4<sup>imidaz</sup>), 159.6 (CH<sup>amidine</sup>); HRMS (ESI) [M+H]<sup>+</sup> found *m/z* 198.0986, calcd for C<sub>7</sub>H<sub>11</sub>N<sub>5</sub>O<sub>2</sub> 198.0986; Anal. Calcd (%): C, 42.64; H, 5.62; N, 35.52. Found: C, 42.68; H, 5.91; N, 35.35.

**6a**: Yellow solid, m. p. 130–135 °C (decopm.), yield 0.060 g (36%). IR (v/cm<sup>-1</sup>): 1140, 1189, 1354, 1444, 1513, 1554, 1603, 2081, 3100; <sup>1</sup>H NMR (400 MHz, DMSO-*d*<sub>6</sub>) δ 3.91 (s, 3H, NCH<sub>3</sub>); 6.21 (s, 1H, CH); 7.91 (s, 1H, CH<sup>imid</sup>).

The structure of diazo compound 6a was also confirmed by X-ray diffraction analysis for monocrystal of 6a.



Fig. S1. Perspective view of compound **6a** (50% probability thermal ellipsoids) as determined by X-ray diffraction analysis.

Supplementary crystallographic data for the compound **6a** (CCDC 1826375) can be obtained free of charge from The Cambridge Crystallographic Data Center via <u>www.ccdc.cam.ac.uk/data\_request/cif</u>.

# General method for synthesis of amidines 8a-c.<sup>7</sup>

A mixture of phenylacetaldehyde (1 mmol), secondary amine **7a-c** (1 mmol), azide **2d** (1 mmol) and CH<sub>3</sub>OH (2 mL) was stirred at 50 °C for 2 h. Then reaction mixture was evaporated in vacuum to dryness and purified by column chromatography (silica gel, ethyl acetate).



(Z)-N-(1-Methyl-4-nitro-1H-imidazol-5-yl)-1-morpholino-2-phenylethan-1-imine (8a). Yellow powder; m. p. 133–137 °C; yield 0.370 g (89%); <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  3.26 (s, 3H, NCH<sub>3</sub>), 3.67 (br. s, 6H, 4H<sup>morph</sup> + CH<sub>2</sub>), 3.88 (s, 4H, H<sup>morph</sup>), 6.98 (d, 2H, *J* 7.2, HPh), 7.09 (s, 1H, CH<sup>imidaz</sup>), 7.20 (t, 1H, *J* 7.3, HPh), 7.26 (dd, 2H, *J* 7.9, 6.6, HPh); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  30.4 (NCH<sub>3</sub>), 36.3 (CH<sub>2</sub>), 45.2 (C<sup>morph</sup>), 47.6 (C<sup>morph</sup>), 66.5 (C<sup>morph</sup>), 127.3 (C<sup>Ph</sup>), 127.6 (2C<sup>Ph</sup>), 129.2 (2C<sup>Ph</sup>), 132.0 (C-2<sup>imidaz</sup>), 133.4 (C-4<sup>imidaz</sup>), 134.9 (C<sup>Ph</sup>), 142.2 (C-5<sup>imidaz</sup>), 164.6 (C=N<sup>amid</sup>); HRMS (ESI) [M+H]<sup>+</sup> found *m*/*z* 330.1561, calcd for C<sub>16</sub>H<sub>19</sub>N<sub>5</sub>O<sub>3</sub> 330.1561; Anal. Calcd (%): C, 58.35; H, 5.81; N, 21.26. Found: C, 58.19; H, 6.0; N, 20.86.



(*Z*)-*N*-(1-Methyl-4-nitro-1H-imidazol-5-yl)-1-piperidiino-2-phenylethan-1-imine (8b). Yellow prisms; yield 0.137 g (42%); m. p. 90–93 °C; IR (v/cm<sup>-1</sup>) 3407, 3030, 2941, 2855, 1583, 1352, 1252; <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.37 (br. s, 1H, H<sup>piper</sup>), 1.63 (br. s, 5H, H<sup>piper</sup>), 3.27 (s, 3H, NCH<sub>3</sub>), 3.25–4.15 (m, 6H, 4H<sup>piper</sup> + CH<sub>2</sub>), 7.02 (d, *J* 7.0 Hz, 2H, H<sup>Ph</sup>), 7.08 (s, 1H, CH<sup>imidaz</sup>), 7.17–7.24 (m, 1H, H<sup>Ph</sup>), 7.24–7.32 (m, 2H, H<sup>Ph</sup>); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 24.4 (C<sup>piper</sup>), 25.0 (C<sup>piper</sup>), 26.5 (C<sup>piper</sup>), 30.2 (NCH<sub>3</sub>), 36.5 (CH<sub>2</sub>), 46.0 (C<sup>piper</sup>), 48.6 (C<sup>piper</sup>), 126.9 (C<sup>Ph</sup>), 127.6 (2C<sup>Ph</sup>), 128.9 (2C<sup>Ph</sup>), 131.8 (C-2<sup>imidaz</sup>), 133.1 (C-4<sup>imidaz</sup>), 135.4 (C<sup>Ph</sup>), 143.0 (C-5<sup>imidaz</sup>), 164.2 (C=N<sup>amid</sup>); MS-EI (*m/z*) 327 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>17</sub>H<sub>21</sub>N<sub>5</sub>O<sub>2</sub>: C, 62.37; H, 6.47; N, 21.39. Found: C, 62.03; H, 6.66; N, 21.24.

Supplementary crystallographic data for the compound **8b** (CCDC 1580079) can be obtained free of charge from The Cambridge Crystallographic Data Center via www.ccdc.cam.ac.uk/data\_request/cif.



(Z)-1-(Azepan-1-yl)-N-(1-methyl-4-nitro-1H-imidazol-5-yl)-2-phenylethan-1-imine (8c). Yellow powder; yield 0.174 g (51%); m. p. 80–82 °C; IR (v/cm<sup>-1</sup>) 3445, 3115, 3029, 2931, 2851, 1580, 1355, 1267;

<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 1.52–1.82 (m, 6H, CH<sub>2</sub><sup>azep</sup>), 1.92 (br. s, 2H, CH<sub>2</sub><sup>azep</sup>), 3.17 (s, 3H, NCH<sub>3</sub>), 3.36 (br. s, 1H, CH<sub>2</sub><sup>azep</sup>), 3.43 (br. s, 1H, CH<sup>azep</sup>), 3.59–3.88 (m, 3H, CH<sup>azep</sup> + CH<sub>2</sub>), 4.18 (br. s, 1H, CH<sup>azep</sup>), 7.00 (d, *J* 7.0 Hz, 2H, CHPh), 7.04 (s, 1H, CH<sup>imidaz</sup>), 7.16–7.32 (m, 3H,CHPh); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>) δ 26.0 (C<sup>azep</sup>), 26.2 (C<sup>azep</sup>), 26.9 (C<sup>azep</sup>), 29.3 (C<sup>azep</sup>), 30.0 (NCH<sub>3</sub>), 36.6 (CH<sub>2</sub>), 49.3 (C<sup>azep</sup>), 50.1 (C<sup>azep</sup>), 126.9 (C<sup>Ph</sup>), 127.8 (2C<sup>Ph</sup>), 128.9 (2C<sup>Ph</sup>), 131.5 (C-2<sup>imidaz</sup>), 133.3 (C-4<sup>imidaz</sup>), 135.5 (C<sup>Ph</sup>), 143.0 (C-5<sup>imidaz</sup>), 165.0 (C=N<sup>amid</sup>); MS-EI (*m/z*) 341 [M]<sup>+</sup>; Anal. Calcd (%) for C<sub>18</sub>H<sub>23</sub>N<sub>5</sub>O<sub>2</sub>: C, 63.32; H, 6.79; N, 20.51. Found: C, 63.23; H, 7.17; N, 20.53.

# References

M. J Frisch, G. W. Trucks, H. B. Schlegel, G. E. Scuseria, M. A. Robb, J. R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G. A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H. P. Hratchian, A. F. Izmaylov, J. Bloino, G. Zheng, J. L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai, T. Vreven, Jr. J. A. Montgomery, J. E. Peralta, F. Ogliaro, M. J. Bearpark, J. Heyd, E. N. Brothers, K. N. Kudin, V. N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A. P. Rendell, J. C. Burant, S. S. Iyengar, J. Tomasi, M. Cossi, N. Rega, N. J. Millam, M. Klene, J. E. Knox, J. B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R. E. Stratmann, O. Yazyev, A. J. Austin, R. Cammi, C. Pomelli, J. W. Ochterski, R. L. Martin, K. Morokuma, V. G. Zakrzewski, G. A. Voth, P. Salvador, J. J. Dannenberg, S. Dapprich, A. D. Daniels, Ö. Farkas, J. B. Foresman, J. V. Ortiz, J. Cioslowski and D. J. Fox. *Gaussian 09*, Gaussian, Inc.: Wallingford, CT, USA, 2009.

2. Y. Zhao and D. G. Truhlar, J. Phys. Chem. A 2004, 108, 6908-6918.

3. Y. Zhao and D. G. Truhlar, J. Phys. Chem. A 2005, 109, 5656-5667.

4. V. Barone and M. Cossi, J. Phys. Chem. A 1998, 102, 1995-2001.

5. M. Cossi, N. Rega, G. Scalmani and V. Barone, J. Comput. Chem. 2003, 24, 669-681.

6. E. D. Glendening, J. K. Badenhoop, A. E. Reed, J. E. Carpenter, J. A. Bohmann, C. M. Morales, C. R. Landis and F. Weinhold, *NBO 6.0*, Theoretical Chemistry Institute, University of Wisconsin, Madison, 2013.

7. I. Efimov, N. Beliaev, T. Beryozkina, P. Slepukhin and V. Bakulev, *Tetrahedron Lett.* 2016, **57**, 1949–1952.



Fig. S2 Calculated geometries of triazolines 11 - 14 corresponding to the lowest free energy conformations.



Fig. S3 Calculated transition state geometries corresponding to formation of triazolines 11 - 14 by 1,3-dipolar cycloaddition of enamines with azides. The shown numbers are the interatomic distances given in angströms.



Fig. S4 Calculated transition state geometries corresponding to the degradation pathways of the triazolines 11 - 14 shown in Scheme 8. The shown numbers are the interatomic distances given in angströms



Fig. S5 Calculated transition state geometries corresponding to the base-catalyzed transformation of triazolines 11 - 14 to the corresponding triazoles as shown in Scheme 9. The base-catalyst is represented by dimethylamine (dma). The shown numbers are the interatomic distances given in angströms.

**Table S1** Second order perturbation analysis of 13' in the NBO basis. The presented results are related to the antibonding orbitals C1–C2 ( $\sigma^*$ ) and C2–N3 ( $\sigma^*$ ).



			13'				
C1–C2 ( $\sigma^*$ ) (acceptor), population = 0.08416			C2–N3 ( $\sigma^*$ ) (acceptor), population = 0.04212				
NBO (donor)	<b>E</b> kcal·mol <sup>-1</sup>	<b>∆E</b> a. u.	<b>F</b> a. u.	NBO (donor)	E kcal·mol <sup>-1</sup>	<b>ДЕ</b> а. и.	<b>F</b> a. u.
N2 (LP)	6.17	0.63	0.056	O1 (LP)	1.85	0.71	0.032
С3-С4 (л)	3.34	0.67	0.042	N4 (LP)	8.64	0.97	0.082
С2-С3 (о)	1.16	1.01	0.031	Ν5C3 (σ)	0.52	1.13	0.022
С1-С2 (о)	0.56	0.91	0.020	С3-С4 (о)	1.39	1.06	0.034
N1-C5 (π)	10.85	0.67	0.076	С3-С4 (π)	0.84	0.68	0.021
N3–N4 (π)	1.42	0.94	0.033	С1-Н1 (о)	4.39	0.87	0.055
Ν2C6 (σ)	1.65	1.00	0.036	N3–N4 (σ)	2.20	1.56	0.052
total (net)	25.15			total (net)	19.83		

 $\sigma$  - sigma bonding orbital;  $\pi$  - pi bonding orbital;  $\sigma^*$  - sigma antibonding orbital; LP - lone pair. *E* - the energy of delocalization (conjugation) of the donor orbital over (with) the acceptor orbital.  $\Delta E$  - the energy gap between the donor and acceptor orbitals. *F* - the element of the Kohn-Sham matrix describing the donor-acceptor interaction (represents spatial overlap).

**Table S2** Second order perturbation analysis of 14' in the NBO basis. The presented results are related to the antibonding orbitals C1–C2 ( $\sigma^*$ ) and C2–N3 ( $\sigma^*$ ).

$ \begin{array}{cccccccccccccccccccccccccccccccccccc$						
C1–C2 (σ*) (acceptor), population = 0.05896			C2-N3 (c	s*) (acceptor), j	population =	= 0.05776
E	ΔΕ	F	NBO	E	$\Delta E$	F
kcal·mol <sup>-1</sup>	а. и.	а. и.	(donor)	kcal·mol <sup>-1</sup>	а. и.	<i>a. u.</i>
4.50 1.10 5.23 0.55 4.53 1.52 0.94 1.90 0.97 1.26	0.70 0.70 0.68 1.04 0.66 1.02 1.17 0.72 0.99 1.05	0.050 0.025 0.053 0.021 0.049 0.035 0.030 0.033 0.028 0.032	N4 (LP) C3–C4 (σ) C3–C4 (π) C1–H1 (σ) N3–N4 (π)	8.52 1.35 7.64 5.21 1.95	0.93 0.97 0.59 0.83 1.53	0.079 0.032 0.060 0.059 0.049
	acceptor), popu <i>E</i> <i>kcal·mol<sup>-1</sup></i> 4.50 1.10 5.23 0.55 4.53 1.52 0.94 1.90 0.97 1.26	E $AE$ $kcal \cdot mol^{-1}$ $a. u.$ $4.50$ $0.70$ $1.10$ $0.70$ $5.23$ $0.68$ $0.55$ $1.04$ $4.53$ $0.66$ $1.52$ $1.02$ $0.94$ $1.17$ $1.90$ $0.72$ $0.97$ $0.99$ $1.26$ $1.05$	$\begin{array}{c c} & & & & & & & \\ \hline & & & & \\ \hline & & & \\ \hline & & & \\ \hline \hline & & \\ \hline & & \\ \hline \hline & & \\ \hline & & \\ \hline \hline & & \\ \hline \hline \\ \hline & & \\ \hline \hline \\ \hline & & \\ \hline \hline \\ \hline \hline & & \\ \hline \hline \hline$	$\begin{array}{c cccccc} & & & & & & & \\ \hline c_7 & & & & & \\ c_8 & & & & \\ \hline c_7 & & & & \\ c_8 & & & \\ \hline c_7 & & & \\ c_8 & & & \\ \hline c_7 & & & \\ c_8 & & \\ \hline c_7 & & & \\ c_8 & & \\ c_8 & & \\ \hline c_7 & & & \\ c_8 & & \\ c_8 & & \\ c_8 & & \\ c_9 & & \\ no_2 & \\ \hline n_1 & & \\ c_9 & & \\ no_2 & \\ \hline n_1 & & \\ c_9 & & \\ no_2 & \\ \hline n_1 & & \\ c_9 & & \\ no_2 & \\ \hline n_1 & & \\ c_9 & & \\ no_2 & \\ \hline n_1 & & \\ c_1 & & \\ n_1 & \\ n_1$	$\begin{array}{c c c c c c c c c c c c c c c c c c c $	$\begin{array}{c c c c c c c c c c c c c c c c c c c $

total (net)	22.5
-------------	------

22.50

total (net) 24.67

 $\sigma$  - sigma bonding orbital;  $\pi$  - pi bonding orbital;  $\sigma^*$  - sigma antibonding orbital; LP - lone pair. E - the energy of delocalization (conjugation) of the donor orbital over (with) the acceptor orbital.  $\Delta E$  - the energy gap between the donor and acceptor orbitals. F - the element of the Kohn-Sham matrix describing the donor-acceptor interaction (represents spatial overlap).













































